337 related articles for article (PubMed ID: 32655838)
1. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and
Tomonari T; Sato Y; Tanaka H; Tanaka T; Fujino Y; Mitsui Y; Hirao A; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Kagiwada H; Kitazawa M; Fukui K; Horimoto K; Takayama T
Oncotarget; 2020 Jun; 11(26):2531-2542. PubMed ID: 32655838
[TBL] [Abstract][Full Text] [Related]
2. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.
Tomonari T; Sato Y; Tani J; Hirose A; Ogawa C; Morishita A; Tanaka H; Tanaka T; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Uchida K; Masaki T; Takayama T
Hepatol Res; 2021 Apr; 51(4):472-481. PubMed ID: 33238074
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma.
Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Takayama T
JGH Open; 2020 Dec; 4(6):1135-1139. PubMed ID: 33319048
[TBL] [Abstract][Full Text] [Related]
4. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
[TBL] [Abstract][Full Text] [Related]
5. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K;
Oncology; 2019; 97(6):334-340. PubMed ID: 31466068
[TBL] [Abstract][Full Text] [Related]
6. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
Tomonari T; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Kawano Y; Okamoto K; Miyamoto H; Sato Y; Takayama T
Clin J Gastroenterol; 2023 Jun; 16(3):438-443. PubMed ID: 36856957
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
[TBL] [Abstract][Full Text] [Related]
8. MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.
Hirao A; Sato Y; Tanaka H; Nishida K; Tomonari T; Hirata M; Bando M; Kida Y; Tanaka T; Kawaguchi T; Wada H; Taniguchi T; Okamoto K; Miyamoto H; Muguruma N; Tanahashi T; Takayama T
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638401
[TBL] [Abstract][Full Text] [Related]
9. What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?
Hiraoka A; Kumada T; Tada T; Kariyama K; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M
Liver Cancer; 2021 Apr; 10(2):115-125. PubMed ID: 33977088
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis.
Hiraoka A; Kumada T; Kariyama K; Takaguchi K; Itobayashi E; Shimada N; Tajiri K; Tsuji K; Ishikawa T; Ochi H; Hirooka M; Tsutsui A; Shibata H; Tada T; Toyoda H; Nouso K; Joko K; Hiasa Y; Michitaka K;
Hepatol Res; 2019 Jan; 49(1):111-117. PubMed ID: 30144256
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old.
Sato R; Moriguchi M; Iwai K; Tsuchiya S; Seko Y; Takahashi A; Kobayashi K; Ogasawara S; Watanabe S; Morimoto N; Kato N; Itoh Y; Aramaki T
Hepatol Res; 2022 Oct; 52(10):859-871. PubMed ID: 35921253
[TBL] [Abstract][Full Text] [Related]
12. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T
Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Niizeki T; Tokunaga T; Takami Y; Wada Y; Harada M; Shibata M; Nakao K; Sasaki R; Hirai F; Shakado S; Yoshizumi T; Itoh S; Yatsuhashi H; Bekki S; Ido A; Mawatari S; Honda K; Sugimoto R; Senju T; Takahashi H; Kuwashiro T; Maeshiro T; Nakamuta M; Aratake Y; Yamashita T; Otsuka Y; Matsumoto S; Sohda T; Shimose S; Murotani K; Tanaka Y
Target Oncol; 2022 Nov; 17(6):643-653. PubMed ID: 36272060
[TBL] [Abstract][Full Text] [Related]
14. Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis.
Ochi H; Tani J; Tomonari T; Taniguchi T; Koizumi Y; Hirose A; Ogawa C; Hiraoka A; Morishita A; Moriya A; Hirooka M; Deguchi A; Symple Study Group
Hepatol Res; 2021 Dec; 51(12):1219-1228. PubMed ID: 34534398
[TBL] [Abstract][Full Text] [Related]
15. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Tsuchiya K; Kurosaki M; Sakamoto A; Marusawa H; Kojima Y; Hasebe C; Arai H; Joko K; Kondo M; Tsuji K; Sohda T; Kimura H; Ogawa C; Uchida Y; Wada S; Kobashi H; Furuta K; Shigeno M; Kusakabe A; Akahane T; Narita R; Yoshida H; Mitsuda A; Ide Y; Matsushita T; Izumi N; On Behalf Of Japanese Red Cross Liver Study Group
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073396
[TBL] [Abstract][Full Text] [Related]
16. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC.
Lee J; Sung PS; Yang H; Lee SK; Nam HC; Yoo SH; Lee HL; Kim HY; Lee SW; Kwon JH; Jang JW; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33371271
[TBL] [Abstract][Full Text] [Related]
17. Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.
Hiraoka A; Kumada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Yokohama K; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo M
Liver Cancer; 2020 Jan; 9(1):73-83. PubMed ID: 32071911
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment.
Kimura M; Yamada S; Go M; Yasuda S; Toyoda H; Usami E
Oncol Lett; 2024 Jul; 28(1):330. PubMed ID: 38807665
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study.
Huang X; Xu L; Ma T; Yin X; Huang Z; Ran Y; Ni Y; Bi X; Che X
Front Oncol; 2021; 11():751159. PubMed ID: 34868952
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population.
Lee SW; Yang SS; Lien HC; Peng YC; Ko CW; Lee TY
J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
